Patents by Inventor Elise C. Kohn
Elise C. Kohn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6790936Abstract: The invention provides for proteins correlated with cellular resistance to carboxyamido-triazole (CAI) which have at least one Src homology 3 (SH3) binding domain, and functionally equivalent compounds.Type: GrantFiled: November 8, 1999Date of Patent: September 14, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Elise C. Kohn, Lance A. Liotta, Young Sook Kim
-
Patent number: 6057346Abstract: A class of calcium-response modification compounds is disclosed which inhibits the activation of retroviral LTR promoters, including the HIV-LTR. This class of compounds are used to delay or suppress the transition of a retroviral infection from a latent to a virulent condition, thereby ameliorating retrovirally caused diseases such as AIDS. The compounds are also useful in cancer treatment, allowing for coordinated therapeutic approaches to retroviral diseases and related cancers such as AIDS and Kaposi's Sarcoma. The compounds are also useful in standardizing in vitro assays of clinical and experimental importance.Type: GrantFiled: December 12, 1994Date of Patent: May 2, 2000Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Elise C. Kohn, Lance A. Liotta, Kevin L. Gardner
-
Patent number: 5981712Abstract: This invention provides for nucleotide sequences that encode CAIR proteins correlated with cellular resistance to carboxyamido-triazole (CAI) and functionally equivalent compounds. The invention further provides for methods of detecting CAI resistance in biological samples and for cell lines that grow and proliferate in the presence of CAI and functionally equivalent compounds.Type: GrantFiled: July 25, 1997Date of Patent: November 9, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Elise C. Kohn, Lance A. Liotta, Young Sook Kim
-
Patent number: 5880129Abstract: A discovery underlying this invention is the concordance between particular cellular signaling mechanisms and cancer cell growth and metastasis. It has now been discovered that certain compounds inhibit the signal transduction required for the maintenance and driving of the malignant process. These compounds are also effective for the in vivo treatment of solid tumors and related disease states. This invention provides a method for the use of these compounds to inhibit the invasion and metastasis of malignant solid tumors in mammals. This invention further provides a method for using related compounds to treat diseases involving aberrant signal transduction pathways. Some of the compounds used in the methods of the present invention are novel and constitute another aspect of this invention.Type: GrantFiled: August 5, 1997Date of Patent: March 9, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Elise C. Kohn, Lance A. Liotta, Christian C. Felder
-
Patent number: 5744492Abstract: Angiogenesis is a composite of regulated proliferation and regulated invasion occuring in a variety of normal and pathologic conditions. Compound 1 and related analogs are useful for inhibiting angiogenesis in a host and offer a novel approach to the treatment of cancer, diabetic retinopathy, hemangiomata, vasculidities and other diseases associated with angiogenesis.Type: GrantFiled: March 10, 1994Date of Patent: April 28, 1998Assignee: United States of AmericaInventors: Elise C. Kohn, Lance A. Liotta, Riccardo Alessandro
-
Patent number: 5705514Abstract: A method of inhibiting the invasion and metastasis of malignant solid tumors in mammals, said method comprising administering to said mammal an anti-proliferative, anti-invasive and anti-metastasis effective amount of a compound selected from the group of formulas consisting of: ##STR1## wherein: p is an integer of from 0 to 4;Ar.sup.1 is a moiety selected from the group consisting of --Ar.sup.2 --X--Ar.sup.3, phenyl, trioxaadamantyl, anthracenyl, anthraquinonyl, naphthyl, phenanthryl, and substituted versions thereof;Ar.sup.2 and Ar.sup.3 are each aromatic moieties independently selected from the group consisting of phenyl, naphthyl, and substituted versions thereof;X is a linking moiety selected from the group consisting of O, S, SO.sub.Type: GrantFiled: May 31, 1995Date of Patent: January 6, 1998Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Elise C. Kohn, Lance A. Liotta, Christian C. Felder
-
Patent number: 5652223Abstract: This invention provides for nucleotide sequences that encode CAIR proteins correlated with cellular resistance to carboxyamido-triazole (CAI) and functionally equivalent compounds. The invention further provides for methods of detecting CAI resistance in biological samples and for cell lines that grow and proliferate in the presence of CAI and functionally equivalent compounds.Type: GrantFiled: March 14, 1994Date of Patent: July 29, 1997Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Elise C. Kohn, Lance A. Liotta, Young Sook Kim
-
Patent number: 5602156Abstract: Calcium homeostasis is an important regulator of MMP-2 transcription, activation and activity. Disclosed herein are compounds which inhibit the expression of matrix metalloproteinases in cells. Pharmaceutical application of these compounds to inhibit the expression of MMPs offers a new approach to cancer treatment as well as treatment for nerve healing, degenerative cartilagenous diseases, decubitus ulcers, arthritis, Alzheimer's disease, wound healing, proliferative retinopathy, proliferative renal diseases, corneal ulcers and fertility problems.Type: GrantFiled: March 10, 1994Date of Patent: February 11, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Elise C. Kohn, Lance A. Liotta
-
Patent number: 5565478Abstract: The present invention provides compositions and methods for the treatment of cancer in a subject wherein compounds of formula I defined herein in combination with paclitaxel or other modified taxane analogs provide enhanced anticancer effects over the effects achieved with the individual compounds.Type: GrantFiled: March 14, 1994Date of Patent: October 15, 1996Assignee: The United States of America as represented by the Department of Health & Human ServicesInventors: Elise C. Kohn, Eddie Reed, Lance A. Liotta
-
Patent number: 5498620Abstract: A compound having the formula: ##STR1## and pharmaceutically acceptable salts thereof.Type: GrantFiled: May 31, 1995Date of Patent: March 12, 1996Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Elise C. Kohn, Lance A. Liotta, Christian C. Felder
-
Patent number: 5482954Abstract: A discovery underlying this invention is the concordance between particular cellular signaling mechanisms and cancer cell growth and metastasis. It has now been discovered that certain compounds inhibit the signal transduction required for the maintenance and driving of the malignant process. These compounds are also effective for the in vivo treatment of solid tumors and related disease states. This invention provides a method for the use of these compounds to inhibit the invasion and metastasis of malignant solid tumors in mammals. This invention further provides a method for using related compounds to treat diseases involving aberrant signal transduction pathways. Some of the compounds used in the methods of the present invention are novel and constitute another aspect of this invention.Type: GrantFiled: July 1, 1994Date of Patent: January 9, 1996Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Elise C. Kohn, Lance A. Liotta, Christian C. Felder
-
Patent number: 5405782Abstract: The present invention relates to an improved method for the determination of therapeutic agents in blood. This method utilizes a solid phase extraction of the solute from plasma followed by reverse phase high performance liquid chromatography on a column of irregularly shaped C-18 modified silica. Comparison of the produced chromatogram with a standard curve provides a precise and accurate quantification of the amount of the solute in blood. Additionally, the extraction and chromatography steps can be readily automated for the rapid determination of multiple samples.Type: GrantFiled: March 31, 1993Date of Patent: April 11, 1995Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Elise C. Kohn, Lance A. Liotta
-
Patent number: 5359078Abstract: A compound having the formula:Y--(CH.sub.2).sub.p --Ar.sup.11 --X--Ar.sup.12wherein:p is an integer of from 0 to 4;Ar.sup.11 and Ar.sup.12 are each aromatic moieties independently selected from the group consisting of phenyl, naphthyl, and substituted versions thereof in which the substituents are members selected from the group consisting of halogen, nitro, carboxyl and alkoxy;X is a linking moiety selected from the group consisting of O, S, SO.sub.2, CO, CHCN, straight chain alkyl, alkoxy, and alkoxyalkyl; andY is a nitrogen-containing heterocyclic moiety.Type: GrantFiled: December 4, 1992Date of Patent: October 25, 1994Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Elise C. Kohn, Lance A. Liotta, Christian C. Felder
-
Patent number: 5132315Abstract: Tumor invasion and metastasis is the most life threatening aspect of cancer. Invasion and metastasis is a multistep process. Cellular functions required for invasion are attachment, locomotion and directed migration. Regulation of these processes may be independent of cell growth. A carboxylamino-imidazole compound was found to be potent inhibitor of tumor cell attachment, motility, invasion, proliferation, and metastasis. This compound and equivalents thereof constitute a cancer treatment agent of particular use in the treatment of peritoneal carcinomatosis of ovarian cancer.Type: GrantFiled: May 19, 1989Date of Patent: July 21, 1992Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Elise C. Kohn, Lance A. Liotta